NCT05237947 2026-03-19
PRISMA
National Cancer Institute (NCI)
Phase 4 Active not recruiting
Clinical Trials
10 trialsNCT07281677 2025-12-15
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
Zhejiang Provincial Center for Disease Control and Prevention
Phase 4 Recruiting
NCT03180034 2025-09-04
ESCUDDO
National Cancer Institute (NCI)
Phase 4 Active not recruiting
NCT00956553 2020-10-01
HPV CSP01
Public Health England
Phase 4 Completed
NCT03105856 2020-08-10
FASTER
Instituto Nacional de Salud Publica, Mexico
Phase 4 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT00534638 2019-11-15
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
GlaxoSmithKline
Phase 4 Completed
NCT00730847 2019-11-05
A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
GlaxoSmithKline
Phase 4 Terminated
NCT02837926 2019-04-10
CoheaHr-WP4
CHU de Reims
Phase 4 Completed
NCT01082861 2010-03-19
TANGO
National Institute for Public Health and the Environment (RIVM)
Phase 4 Terminated